GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK) posted its quarterly earnings results on Tuesday. The company reported GBX 54.10 earnings per share for the quarter, Digital Look Earnings reports. GSK had a return on equity of 35.78% and a net margin of 17.78%.

GSK Stock Performance

LON GSK opened at GBX 1,958.50 on Thursday. The stock has a market capitalization of £78.45 billion, a PE ratio of 13.78, a P/E/G ratio of 1.24 and a beta of 0.30. The business has a 50 day simple moving average of GBX 1,937.92 and a two-hundred day simple moving average of GBX 1,991.49. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. GSK has a 1-year low of GBX 1,288.61 and a 1-year high of GBX 2,282.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Citigroup reduced their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,950 target price on shares of GSK in a research report on Monday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,041.43.

Insiders Place Their Bets

In other news, insider Vishal Sikka bought 1,266 shares of the stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of GBX 5,069 per share, for a total transaction of £64,173.54. Also, insider Jeannie Lee bought 802 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Insiders have bought a total of 3,625 shares of company stock valued at $13,495,004 in the last quarter. 0.20% of the stock is currently owned by insiders.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: Broker support: Jefferies reaffirmed its “buy” rating and set a GBX 2,500 price target, indicating substantial potential upside from recent trading levels. Digital Look broker views
• Positive Sentiment: Pipeline progress: Partner Hansoh reported positive late-stage trial results for a bone-cancer therapy licensed by GSK. The outcome supports the company’s effort to replenish its drug pipeline and could strengthen future growth prospects. GSK licensed cancer therapy trial report
• Positive Sentiment: Efficiency and margin focus: GSK plans approximately £1.9 billion in annual savings, or about $2.5 billion in restructuring-related savings, primarily from mature products, procurement and its supply chain. Management also raised its margin outlook, with savings intended to fund research and development and accelerate new medicines. GSK savings and R&D report
• Neutral Sentiment: Quarterly results: GSK reported quarterly earnings of GBX 54.10 per share, alongside a 17.78% net margin and 35.78% return on equity. The available report does not provide a comparable earnings estimate or detailed outlook change. GSK quarterly earnings report
• Neutral Sentiment: Analyst disagreement: Deutsche Bank maintained a “hold” rating, contrasting with Jefferies’ bullish view and highlighting uncertainty around GSK’s restructuring and longer-term growth. Deutsche Bank GSK rating report
• Negative Sentiment: Execution and workforce risks: GSK plans to close its historic Stevenage site, move research activity to Cambridge and cut jobs. While these moves may reduce costs, they could disrupt operations, trigger restructuring expenses and create execution risks. GSK Stevenage site closure report
• Negative Sentiment: Patent-cliff concerns: The cost-cutting program is partly intended to prepare GSK for upcoming loss-of-exclusivity pressures. Investors may remain cautious until the company demonstrates that savings can offset product erosion and produce successful replacement drugs. GSK restructuring and patent cliff report

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.